A Novel Nuclear Function for the Interleukin-17 Signaling Adaptor Protein Act1
AffiliationUniv Arizona, Sch Pharm, Dept Pharmacol & Toxicol
MetadataShow full item record
PublisherPUBLIC LIBRARY SCIENCE
CitationA Novel Nuclear Function for the Interleukin-17 Signaling Adaptor Protein Act1 2016, 11 (10):e0163323 PLOS ONE
Rights© 2016 Velichko et al. This is an open access article distributed under the terms of the Creative Commons Attribution License.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractIn the context of the human airway, interleukin-17A (IL-17A) signaling is associated with severe inflammation, as well as protection against pathogenic infection, particularly at mucosal surfaces such as the airway. The intracellular molecule Act1 has been demonstrated to be an essential mediator of IL-17A signaling. In the cytoplasm, it serves as an adaptor protein, binding to both the intracellular domain of the IL-17 receptor as well as members of the canonical nuclear factor kappa B (NF-kappa B) pathway. It also has enzymatic activity, and serves as an E3 ubiquitin ligase. In the context of airway epithelial cells, we demonstrate for the first time that Act1 is also present in the nucleus, especially after IL-17A stimulation. Ectopic Act1 expression can also increase the nuclear localization of Act1. Act1 can up-regulate the expression and promoter activity of a subset of IL-17A target genes in the absence of IL-17A signaling in a manner that is dependent on its N- and C-terminal domains, but is NF-kappa B independent. Finally, we show that nuclear Act1 can bind to both distal and proximal promoter regions of DEFB4, one of the IL-17A responsive genes. This transcriptional regulatory activity represents a novel function for Act1. Taken together, this is the first report to describe a non-adaptor function of Act1 by directly binding to the promoter region of IL-17A responsive genes and directly regulate their transcription.
VersionFinal published version
SponsorsNational Institute of Health [AI061695, AI113526, HL096373, T32 HL07013, ES00628, HL097087]; Clinical Innovator Award from Flight Attendant Medical Research Institute [123055-CIA]
- Requirement for both JAK-mediated PI3K signaling and ACT1/TRAF6/TAK1-dependent NF-kappaB activation by IL-17A in enhancing cytokine expression in human airway epithelial cells.
- Authors: Huang F, Kao CY, Wachi S, Thai P, Ryu J, Wu R
- Issue date: 2007 Nov 15
- Requirements for two proximal NF-kappaB binding sites and IkappaB-zeta in IL-17A-induced human beta-defensin 2 expression by conducting airway epithelium.
- Authors: Kao CY, Kim C, Huang F, Wu R
- Issue date: 2008 May 30
- Act1, a U-box E3 ubiquitin ligase for IL-17 signaling.
- Authors: Liu C, Qian W, Qian Y, Giltiay NV, Lu Y, Swaidani S, Misra S, Deng L, Chen ZJ, Li X
- Issue date: 2009 Oct 13
- Persistent stimulation with interleukin-17 desensitizes cells through SCFβ-TrCP-mediated degradation of Act1.
- Authors: Shi P, Zhu S, Lin Y, Liu Y, Liu Y, Chen Z, Shi Y, Qian Y
- Issue date: 2011 Nov 1
- IFN regulatory factor-1 is required for the up-regulation of the CD40-NF-kappa B activator 1 axis during airway inflammation.
- Authors: Zhao Z, Qian Y, Wald D, Xia YF, Geng JG, Li X
- Issue date: 2003 Jun 1